title: Biopharmaceutical discovery and production in yeast.
abstract: The selection of an expression platform for recombinant biopharmaceuticals is often centered upon suitable product titers and critical quality attributes, including post-translational modifications. Although notable differences between microbial, yeast, plant, and mammalian host systems exist, recent advances have greatly mitigated any inherent liabilities of yeasts. Yeast expression platforms are important to both the supply of marketed biopharmaceuticals and the pipelines of novel therapeutics. In this review, recent advances in yeast-based expression of biopharmaceuticals will be discussed. The advantages of using glycoengineered yeast as a production host and in the discovery space will be illustrated. These advancements, in turn, are transforming yeast platforms from simple production systems to key technological assets in the discovery and selection of biopharmaceutical lead candidates.
authors.affiliation: GlycoFi, Biologics Research, Merck & Co., Inc., 16 Cavendish Court, Lebanon, NH 03766, USA.
authors.forename: Michael A
authors.initials: MA
authors.lastname: Meehl
authors.affiliation: GlycoFi, Biologics Research, Merck & Co., Inc., 16 Cavendish Court, Lebanon, NH 03766, USA. Electronic address: andy_stadheim@merck.com.
authors.forename: Terrance A
authors.initials: TA
authors.lastname: Stadheim
mesh_terms: D000818:Animals; D001688:Biological Products / Q000378:metabolism*; D006031:Glycosylation; D010944:Plants / Q000378:metabolism; D011499:Protein Processing, Post-Translational; D011994:Recombinant Proteins / Q000235:genetics / Q000378:metabolism*; D012441:Saccharomyces cerevisiae / Q000235:genetics / Q000378:metabolism*; D013678:Technology, Pharmaceutical / Q000379:methods*; D015003:Yeasts / Q000235:genetics / Q000378:metabolism*
chemical_list: D001688:Biological Products; D011994:Recombinant Proteins